Adverse Reaction "Overview" Section Would Reduce Clarity - PhRMA Says
Executive Summary
FDA's proposed "Overview" section for adverse reaction labeling would make labeling more confusing for prescribers, the Pharmaceutical Research & Manufacturers of America said in comments on the agency's draft guidance.